Novo Nordisk aims to submit hemophilia drug for approval this year

Phase III results have confirmed Novo Nordisk’s faith in concizumab, which treats hemophilia A and B, and the company is now expecting to submit the drug for regulatory approval in H2 2022.

One of Novo's potential hemophilia drugs has demonstrated the desired effects in a phase III trial, dubbed Explorer 7

by mikkel aabenhus hemmingsen, translated by daniel pedersen

Before the year is over, Novo Nordisk will have submitted hemophilia drug concizumab for review by regulatory authorities, the company reports in its first quarterly report for 2022 on Friday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Former Demant Executive Vice President Arne Boye Nielsen was found responsible for creating an "unsafe psychological work environment" in an internal legal investigation. | Foto: Demant / Pr

Hearing health

Demant Foundation continues to work with ousted Demant executive

While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.

Sacked Demant executive receives USD 2.6 million golden handshake

Demant Board has "full confidence" in management's handling of unsafe work environment

For subscribers

Hearing health

CHMP recommends ten new medicines in June

For subscribers

Foto: George Frey/Reuters/Ritzau Scanpix

Pharma & biotech

Cosmetic Ozempic use under fire in EU amid drug shortages

Pharma & biotech

Novo to limit Wegovy’s China launch to avoid global disruption

Pharma & biotech

Analyst on Novo Nordisk writedown: "It is a reminder of the risks"

Pharma & biotech

Novo Nordisk snaps up partner's hemophilia candidate and gene editing technology

For subscribers

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Novo Nordisk blood pressure candidate ends in USD 817m flop

Novo Nordisk acquired ocedurenone from KBP Biosciences in 2023.

CHMP recommends conditional approval for Genmab and Abbvie's epcoritamab

Epcoritamab may represent a new therapeutic option for patients with relapsed or refractory follicular lymphoma, according to Genmab.

For subscribers

Pharmacosmos calls off the hunt for investors

Pharmacosmos will make acquisitions without the use of new outside investors.

For subscribers

Bavarian Nordic expects Jynneos to be fully effective against new mpox variant

Bavarian Nordic’s vaccine Jynneos is the only approved vaccine against the disease mpox.

Foto: Medwatch/photo by Ulrich Quistgaard

Genmab cancer drug approved in new indication in US

Epkinly has become the first and only subcutaneously administered T-cell engaging bispecific antibody approved in the US for the treatment of this patient population.

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Hearing health

Demant Foundation continues to work with ousted Demant executive

While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.

For subscribers

Pharma & biotech

Cosmetic Ozempic use under fire in EU amid drug shortages

The success of Novo Nordisk’s Ozempic and Wegovy as well as blockbuster shots made by rival Eli Lilly has left some patients with diabetes struggling to continue their treatment.

Pharma & biotech